Posted by Michael Wonder on 25 Oct 2019
Making new drugs is hard. So is pricing them.
25 October 2019 - What's harder, making new drugs, or pricing them?
Biogen might say it's the former. After scrapping its aducanumab therapy for Alzheimer's in March, the company reversed course this week and said it will seek approval on the back of some new, more encouraging trial data.
A number of drug makers have been burned in seeking a treatment for the memory-robbing disease, and Biogen was sheared of about a quarter of its market value earlier this year when it looked as though it might join their ranks. The clouds that gathered around Biogen have parted, for now.
